Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Tesla, Inc. — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Tesla, Inc. trades at $361.43 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 196.8× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Tesla, Inc. for 88 Days on average.
| SYRE | TSLA | |
|---|---|---|
Market Cap | $7.52B | $1.48T |
Volume | 1,441,031 | 18,314,332 |
Sector | Health | Consumer Cyclical |
52-Week High | $108.92 | $489.88 |
52-Week Low | $22.18 | $298.16 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $6.52B | $1.45T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Tesla (TSLA) trades at $375.20, down 0.75% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The stock faces fundamental headwinds with a high P/E ratio of 347.44 and declining profit margins, though it has beaten earnings estimates in two of the last three quarters. Recent news highlights regulatory approval for its driver-assistance software in Europe and a strategic pivot toward robotics and AI.
The outlook remains bifurcated: long-term growth potential in autonomy and energy storage offers upside, but near-term risks include intense EV competition, earnings volatility, and rich valuations. Analyst consensus is a Buy with a $441.36 price target, yet investor sentiment is cautious due to delivery misses and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
